- Form 4 for Geary Richard S filed 11 03 2025 - ir. ionispharma. com
The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc any security holder of Ionis Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4
- Ionis Pharmaceuticals to present at upcoming investor conferences
ABOUT IONIS PHARMACEUTICALS, INC As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective
- Ionis to present at upcoming investor conferences | Ionis . . .
Please check www ionispharma com for the latest information A live webcast of the presentations will be available on the Investors Media section of the Ionis website The replays will be available within 48 hours and will be archived for a limited time
- Isis Pharmaceuticals Reports Positive Phase 2 Data: ISIS 113715 . . .
The Investor Relations website contains information about Ionis Pharmaceuticals, Inc 's business for stockholders, potential investors, and financial analysts
- Draft - ir. ionispharma. com
In this presentation, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and its subsidiaries
- Ionis announces FDA acceptance of New Drug Application for eplontersen . . .
"We are excited by today's FDA acceptance of our NDA filing as it brings Ionis and our partner, AstraZeneca, one step closer to making eplontersen available to patients with ATTR polyneuropathy," said Eugene Schneider, M D , executive vice president and chief clinical development officer at Ionis
- Q2:22 Financial Results and Business Update
These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2021, and our most recent Form 10-Q quarterly filing, which are on file with the Securities and Exchange Commission
- Mipomersen Phase 3 Study in HoFH Patients Featured in The Lancet
The Investor Relations website contains information about Ionis Pharmaceuticals, Inc 's business for stockholders, potential investors, and financial analysts
|